UNSPSC 51352309: Toripristone

This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 711D76P884. European Medicines Agency schedules Toripristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11198MIG. Toripristone generally arises in the molecular formula C31H39NO2. The term TORIPRISTONE is an International Non-Proprietary Name or INN. TORIPRISTONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule toripristone under HS 29372900 and SITC 54153. As of Q4 2014, TORIPRISTONE remains the US FDA Preferred Term for this commodity. Toripristone bears US NLM identifiers UMLS ID C2984007 and NCI Concept Code C91055. SMILES: OC1(C2(C(C3C(=C4C(=CC(=O)CC4)CC3)C(C2)c2ccc(N(C(C)C)C)cc2)CC1)C)C#CC.

UNSPSC 51352309 Toripristone is a Commodity code capturing pharmaceutical products supplied through cooperative purchasing agreements to state and local government facilities. State and local governments buying under this code procure generic pharmaceuticals and over-the-counter products through multistate cooperative purchasing vehicles, with recent activity centered on establishing master supply agreements that distribute products via authorized wholesalers to participating agencies across multiple states. The work involves manufacturers or authorized distributors providing comprehensive product data, maintaining compliance with FDA manufacturing standards and supply chain security regulations, and pricing products competitively against established benchmarks such as WAC or net pricing formats. Issuing bodies are predominantly state procurement offices administering cooperative purchasing alliances on behalf of participating state agencies, counties, and municipalities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout recent buyer.

The code shows recent activity centered in Minnesota and Oregon through MMCAP's current solicitation. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The RFP emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with cGMP and DSCSA standards, maintenance of relationships with at least two of three authorized wholesalers, and demonstration of multiple pricing structures including flat price, net price formats, and WAC-minus options. Awarded vendors must obtain $5,000,000 per-occurrence commercial general liability insurance and $2,000,000 network security and professional liability coverage, with contract terms of two years for new responders and potential extensions at MMCAP's discretion through June 30, 2028.